The Facts.
Media

Evaluating Western Midstream: Insights From 6 Financial Analysts

Latest Ratings for WES Date Firm Action From To Mar 2022 Credit Suisse Maintains Outperform Mar 2022 Mizuho Maintains Buy Dec 2021 Wells Fargo Maintains Overweight View More Analyst Ratings for WES View the Latest Analyst Ratings read more ​  ​Latest Ratings for WES DateFirmActionFromTo Mar 2022Credit SuisseMaintainsOutperform Mar 2022MizuhoMaintainsBuy Dec 2021Wells FargoMaintainsOverweight View More

Read More
Media

What’s Going On With General Motors Today?

General Motors Company (NYSE: GM) shares are trading lower Friday due to several recent developments. Here’s what you need to know. read more ​  ​General Motors Company (NYSE: GM) shares are trading lower Friday due to several recent developments. Here’s what you need to know. read more 

Read More
Media

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

Bluebird Bio’s Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns. Latest Ratings for BLUE Date Firm Action From To Mar 2022 Wells Fargo Maintains Equal-Weight Mar 2022 Morgan Stanley Maintains Underweight Mar 2022 Barclays Downgrades Equal-Weight Underweight View More Analyst Ratings for

Read More
Media

Trump’s Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley

U.S. election results and inflation concerns pressure renewable energy stocks. Morgan Stanley downgrades key clean tech players while backing GE Vernova and First Solar. Latest Ratings for SEDG Date Firm Action From To Mar 2022 B of A Securities Maintains Buy Feb 2022 Northland Capital Markets Maintains Underperform Feb 2022 Citigroup Maintains Buy View More

Read More
Media

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. read more ​  ​Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. read more 

Read More
Media

Looking Into Monday.Com’s Recent Short Interest

read more ​  ​read more 

Read More
Media

Looking Into SPS Commerce’s Recent Short Interest

read more ​  ​read more 

Read More
Media

How Is The Market Feeling About Bancorp?

read more ​  ​read more 

Read More
Media

Crude Oil Dips Over 2%; Bloom Energy Shares Spike Higher

read more ​  ​read more 

Read More
Media

Stocks Tumble As Traders Rethink Fed’s Action, VIX Spikes 17%, Nasdaq Erases Back Post-Trump Gains: What’s Driving Markets Friday?

Risk aversion dominated Wall Street in the final session of the week, driving sharp losses across major indices. read more ​  ​Risk aversion dominated Wall Street in the final session of the week, driving sharp losses across major indices. read more 

Read More
This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.